How do tumors actively escape from host immunosurveillance?

Archivum Immunologiae et Therapiae Experimentalis

Volumn 58, Issue 6, 2010, Pages 435-448

  Wilczyński, Jacek R ^a   Duechler, Markus ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Immunoediting; Immunosurveillance; Tumor

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL INFILTRATION; CELL INTERACTION; DENDRITIC CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOREGULATION; IMMUNOSURVEILLANCE; INFLAMMATORY CELL; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; REVIEW; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANIMALS; CELL PROLIFERATION; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; TUMOR ESCAPE;

EID: 78649319743     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-010-0102-1     Document Type: Review

References (194)

1. Z Abdel-Wahab MF Kalady S Emani, et al. 2003 Induction of anti-melanoma CTL response using DC transfected with mutated mRNA encoding full-length Melan-A/MART-1 antigen with an A27L amino acid substitution Cell Immunol 224 86 97 1:CAS:528:DC%2BD3sXos1Cjt7w%3D 14609574
2. A Agarwal M Rani GK Saha, et al. 2003 Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma Immunol Invest 32 17 30 1:CAS:528:DC%2BD3sXjsFylsrY%3D 12722939
3. M Augsten C Hägglöf E Olsson, et al. 2009 CXCL14 is an autocrine growth factor for fibroblasts and acts as a multimodal stimulator of prostate tumor growth Proc Natl Acad Sci USA 106 3414 3419 1:CAS:528: DC%2BD1MXivF2jtr8%3D 19218429
4. F Balkwill 2002 Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13 135 141 1:CAS:528:DC%2BD38XitFWhsrY%3D 11900989
5. F Balkwill A Mantovani 2001 Inflammation and cancer: back to Virchow? Lancet 357 539 545 1:CAS:528:DC%2BD3MXhsVKltb0%3D 11229684
6. D Bell P Chomarat D Broyles, et al. 1999 In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas J Exp Med 190 1417 1426 1:CAS:528: DyaK1MXnsVams7g%3D 10562317
7. A Ben-Baruch 2006 Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators Semin Cancer Biol 16 38 52 1:CAS:528:DC%2BD28XotVCmug%3D%3D 16139507
8. F Benchetrit A Ciree V Vives, et al. 2002 Interleukin-17 inhibits tumor cell growth by means of a T-cell dependent mechanism Blood 99 2114 2121 1:CAS:528:DC%2BD38XitF2nurY%3D 11877287
9. LE Benjamin E Keshet 1997 Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal Proc Natl Acad Sci USA 94 8761 8766 1:CAS:528:DyaK2sXltlWhtr4%3D 9238051
10. K Bennaceur JA Chapman JL Touraine, et al. 2009 Immunosuppressive networks in the tumour environment and their effect in dendritic cells Biochim Biophys Acta 1795 16 24 1:CAS:528:DC%2BD1MXhsVyisg%3D%3D 18675885
11. C Bergmann L Strauss R Zeidler, et al. 2007 Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma Cancer Res 67 8865 8873 1:CAS:528:DC%2BD2sXhtVCit7jF 17875728
12. E Bettelli Y Carrier W Gao, et al. 2006 Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells Nature 441 235 238 1:CAS:528:DC%2BD28XksVGns7g%3D 16648838
13. Y Bi G Liu R Yang 2007 Th17 cell induction and immune regulatory effects J Cell Physiol 211 273 278 1:CAS:528:DC%2BD2sXktVSrtr8%3D 17311299
14. SK Biswas L Gangi S Paul, et al. 2006 A distinct and unique transcriptional program expressed by tumor associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation) Blood 107 2112 2122 1:CAS:528:DC%2BD28XitFChtLc%3D 16269622
15. T Blankenstein 2005 The role of tumor stroma in the interaction between tumor and immune system Curr Opin Immunol 17 180 186 1:CAS:528: DC%2BD2MXit1ChtL0%3D 15766679
16. C Bogdan 2001 Nitric oxide and the immune response Nat Immunol 2 907 916 1:CAS:528:DC%2BD3MXnsVCisrs%3D 11577346
17. SK Bunt P Sinha VK Clements, et al. 2006 Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression J Immunol 176 284 290 1:CAS:528:DC%2BD2MXhtlagtL7I 16365420
18. Bunt SK, Hanson EM, Sinha P et al (2007a) Tumor-associated myeloid-derived suppressor cells. In: Prendergast GC, Jaffee EM (eds) Cancer immunotherapy: immune suppression and tumor growth. Elsevier, Basel
19. SK Bunt L Yang P Sinha, et al. 2007 Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid derived suppressor cells and limits tumor progression Cancer Res 67 10019 10026 1:CAS:528:DC%2BD2sXhtFOnsLrF 17942936
20. + T cell infiltration enables murine skin tumours to progress Cancer Immunol Immunother 52 396 402 1:CAS:528:DC%2BD3sXjsFejsb8%3D 12739069
21. Y Cao 2005 Tumor angiogenesis and therapy Biomed Pharmacother 59 suppl 2 S340 S343 1:CAS:528:DC%2BD28Xpt1CmtQ%3D%3D 16507405
22. D Cao M Hou Y Guan, et al. 2009 Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications BMC Cancer 9 432 440 20003271
23. + T cells: when, where, and how Annu Rev Immunol 24 519 540 1:CAS:528:DC%2BD28XkvFSqtLs%3D 16551258
24. JK Chan A Magistris V Loizzi, et al. 2005 Mast cell density, angiogenesis, blood clotting, and prognosis in women with advanced ovarian cancer Gynecol Oncol 99 20 25 1:CAS:528:DC%2BD2MXhtVartrjO 16055178
25. CC Chang SP Murphy S Ferrone 2003 Differential in vivo and in vitro HLA-G expression in melanoma cells: potential mechanisms Hum Immunol 64 1057 1063 1:CAS:528:DC%2BD3sXos1Kgu7g%3D 14602236
26. + regulatory T lymphocytes in malignant pleural effusion Am J Respir Crit Care Med 172 1434 1439 16151041
27. A Chlenski S Liu SL Cohn 2003 The regulation of angiogenesis in neuroblastoma Cancer Lett 197 47 52 1:CAS:528:DC%2BD3sXls1Cnsbc%3D 12880959
28. S Cloosen J Arnold M Thio, et al. 2007 Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: implications for self-tolerance and tumor therapy Cancer Res 67 3919 3926 1:CAS:528:DC%2BD2sXkt1Kiu7w%3D 17440107
29. M Colonna G Trinchieri YJ Liu 2004 Plasmacytoid dendritic cells in immunity Nat Immunol 5 1219 1226 1:CAS:528:DC%2BD2cXpvV2rsbg%3D 15549123
30. LM Coussens Z Werb 2002 Inflammation and cancer Nature 420 860 867 1:CAS:528:DC%2BD38XpsFygtb4%3D 12490959
31. T Cramer Y Yamanishi BE Clausen, et al. 2003 HIF-1alpha is essential for myeloid cell-mediated inflammation Cell 112 645 657 1:CAS:528: DC%2BD3sXitFykurY%3D 12628185
32. S Dabiri D Huntsman N Makretsov, et al. 2004 The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis Mod Pathol 17 690 695 15044916
33. + regulatory T cells in the inhibition of antitumor CD8 T-cell responses Cancer Res 65 8479 8486 1:CAS:528: DC%2BD2MXhtVShsbfM 16166328
34. ES Doubrovina MM Doubrovin E Vider, et al. 2003 Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma J Immunol 171 6891 6899 1:CAS:528:DC%2BD3sXpsV2rur0%3D 14662896
35. W Dummer BC Bastian N Ernst, et al. 1996 Interleukin-10 production in malignant melanoma: preferential detection of IL-10-secreting tumor cells in metastatic lesions Int J Cancer 66 607 610 1:STN:280:DyaK283hs1Gnuw%3D%3D 8647620
36. GP Dunn LJ Old RD Schreiber 2004 The immunobiology of cancer immunosurveillance and immunoediting Immunity 21 137 148 1:CAS:528: DC%2BD2cXnsVKltrY%3D 15308095
37. SE Erdman VP Rao W Olipitz, et al. 2010 Unifying roles for regulatory T cells and inflammation in cancer Int J Cancer 126 1651 1665 1:CAS:528: DC%2BC3cXhtl2itL0%3D 19795459
38. J Fang M Ding L Yang, et al. 2007 PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis Cell Signal 19 2487 2497 1:CAS:528: DC%2BD2sXhtFKitrrP 17826033
39. G Ferlazzo B Morandi A D'Agostino, et al. 2003 The interaction between NK cells and dendritic cells in bacterial infections results in rapid induction of NK cell activation and in the lysis of uninfected dendritic cells Eur J Immunol 33 306 313 1:CAS:528:DC%2BD3sXhtlOktL8%3D 12548561
40. N Ferrara 2010 Pathways mediating VEGF-independent tumor angiogenesis Cytokine Growth Factor Rev 21 21 26 1:CAS:528:DC%2BC3cXivFKgsrg%3D 20005148
41. F Fiore B Nuschak S Peola, et al. 2005 Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells Eur J Immunol 35 1155 1163 1:CAS:528: DC%2BD2MXjslSgtb4%3D 15761844
42. ER Fisher SM Paik H Rockette, et al. 1989 Prognostic significance of eosinophils and mast cells in rectal cancer: findings from the National Surgical Adjuvant Breast and Bowel Project (protocol R-01) Hum Pathol 20 159 163 1:STN:280:DyaL1M7itF2lsg%3D%3D 2562788
43. J Folkman 2003 Angiogenesis and apoptosis Semin Cancer Biol 13 159 167 1:CAS:528:DC%2BD3sXitlWnsLg%3D 12654259
44. S Fujii T Takayama M Asakura, et al. 2009 Dendritic cell-based cancer immunotherapies Arch Immunol Ther Exp 57 189 198
45. R Fujiwaki K Iida H Kanasaki, et al. 2002 Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase Hum Pathol 33 213 219 1:CAS:528:DC%2BD38XjsFGisb8%3D 11957147
46. DS Galinsky H Nechushtan 2008 Mast cells and cancer - no longer just basic science Crit Rev Oncol Hematol 68 115 130 18632284
47. O Gallo E Masini B Bianchi, et al. 2002 Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma Hum Pathol 33 708 714 1:CAS:528:DC%2BD38XnsVCrur8%3D 12196922
48. Y Gao W Yang M Pan, et al. 2003 Gamma delta T cells provide an early source of interferon gamma in tumor immunity J Exp Med 198 433 442 1:CAS:528:DC%2BD3sXmt1Ggsr8%3D 12900519
49. A Garcia-Lora I Algarra F Garrido 2003 MHC class I antigens, immune surveillance and tumor immune escape J Cell Physiol 195 346 355 1:CAS:528:DC%2BD3sXjs1yhs7w%3D 12704644
50. + regulatory T cell proliferation J Exp Med 202 919 929 1:CAS:528:DC%2BD2MXhtVygt73F 16186184
51. E Gilboa 2001 The risk of autoimmunity associated with tumor immunotherapy Nat Immunol 2 789 792 1:CAS:528:DC%2BD3MXmsFehsrk%3D 11526387
52. AQ Gomes DV Correia B Silva-Santos 2007 Non-classical major histocompatibility complex proteins as determinants of tumour immunosurveillance EMBO Rep 8 1024 1030 1:CAS:528:DC%2BD2sXht1eqs73E 17972902
53. RM Gorczynski Z Chen J Hu, et al. 2001 Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice Clin Exp Immunol 126 220 229 1:CAS:528:DC%2BD3MXotlCqtbs%3D 11703364
54. A Gorter S Meri 1999 Immune evasion of tumor cells using membrane-bound complement regulatory proteins Immunol Today 20 576 582 1:CAS:528: DyaK1MXns1SgurY%3D 10562709
55. WH Gotlieb JS Abrams JM Watson, et al. 1992 Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers Cytokine 4 385 390 1:CAS:528:DyaK3sXmt1eqtb0%3D 1421000
56. A Greenhough HJ Smartt AE Moore, et al. 2009 The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment Carcinogenesis 30 377 386 1:CAS:528:DC%2BD1MXivFSiuro%3D 19136477
57. MJ Grimshaw S Naylor FR Balkwill 2002 Endothelin-2 is a hypoxia induced autocrine survival factor for breast tumor cells Mol Cancer Ther 1 1273 1281 1:CAS:528:DC%2BD3sXmtFalsA%3D%3D 12516960
58. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis Nature 389 737 742 1:CAS:528:DyaK2sXmvVSgtb0%3D 9338786
59. Y Hayakawa V Screpanti H Yagita, et al. 2004 NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy J Immunol 172 123 129 1:CAS:528:DC%2BD3sXpvFeht7w%3D 14688317
60. M Hishii JT Kurnick T Ramirez-Montagut, et al. 1999 Studies of the mechanism of cytolysis by tumour-infiltrating lymphocytes Clin Exp Immunol 116 388 394 1:CAS:528:DyaK1MXjvFOku7Y%3D 10361224
61. T Hiura H Kagamu S Miura, et al. 2005 Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression J Immunol 175 5058 5066 1:CAS:528:DC%2BD2MXhtVylsbjK 16210609
62. DR Hodge B Peng JC Cherry, et al. 2005 Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation Cancer Res 65 4673 4682 1:CAS:528:DC%2BD2MXks1Ohtb8%3D 15930285
63. C Huang J Li WY Ma, et al. 1999 JNK activation is required for JB6 cell transformation induced by tumor necrosis factor-alpha but not by 12-O-tetradecanoylphorbol-13-acetate J Biol Chem 274 29672 29676 1:CAS:528:DyaK1MXmvVajsrw%3D 10514437
64. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host Cancer Res 66 1123 1131 1:CAS:528:DC%2BD28XlsFOgug%3D%3D 16424049
65. A Iamaroon S Pongsiriwet S Jittidecharaks, et al. 2003 Increase of mast cells and tumor angiogenesis in oral squamous cell carcinoma J Oral Pathol Med 32 195 199 12653857
66. TS Jani J DeVecchio T Mazumdar, et al. 2010 Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines (cc) and is synergistic in combination with TRAIL or oxaliplatin J Biol Chem 285 19162 19172 1:CAS:528:DC%2BC3cXnt1Cntbk%3D 20424169
67. + regulatory T cells J Immunol 177 896 904 1:CAS:528: DC%2BD28XmsVartr8%3D 16818744
68. + T cell infiltration in melanocytic lesions in HLA-A2 phenotype patients J Dermatol Sci 25 36 44 1:CAS:528: DC%2BD3MXitlygsw%3D%3D 11154862
69. R Kalluri M Zeisberg 2006 Fibroblasts in cancer Nat Rev Cancer 6 392 401 1:CAS:528:DC%2BD28XjslGitLw%3D 16572188
70. T Kammertoens T Schüler T Blankenstein 2005 Immunotherapy: target the stroma to hit the tumor Trends Moll Med 11 225 231 1:CAS:528: DC%2BD2MXjvFemtrg%3D
71. AE Karnoub AB Dash AP Vo, et al. 2007 Mesenchymal stem cells within tumour stroma promote breast cancer metastasis Nature 449 557 563 1:CAS:528:DC%2BD2sXhtFagt7fI 17914389
72. HT Khong NP Restifo 2002 Natural selection of tumor variants in the generation of "tumor escape" phenotypes Nat Immunol 3 999 1005 1:CAS:528:DC%2BD38Xot1Chs7o%3D 12407407
73. R Kim M Emi K Tanabe 2005 Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses Cancer Biol Ther 4 924 933 1:CAS:528:DC%2BD28XkvVOiu7Y%3D 16177562
74. KS Kim S Sengupta M Berk, et al. 2006 Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophospatidic acid induces ovarian tumor metastasis in vivo Cancer Res 66 7983 7990 1:CAS:528: DC%2BD28XotFWqt74%3D 16912173
75. R Kim M Emi K Tanabe 2007 Cancer immunoediting from immune surveillance to immune escape Immunology 121 1 14 1:CAS:528:DC%2BD2sXltFarsb8%3D 17386080
76. S Kruger-Krasagakes K Krasagakis C Garbe, et al. 1994 Expression of interleukin 10 in human melanoma Br J Cancer 70 1182 1185 1:STN:280: DyaK2M%2FntFyltw%3D%3D 7981073
77. I Kryczek L Zou P Rodriguez, et al. 2006 B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma J Exp Med 203 871 881 1:CAS:528:DC%2BD28Xjsl2is74%3D 16606666
78. S Kusmartsev DI Gabrilovich 2006 Role of immature myeloid cells in mechanisms of immune evasion in cancer Cancer Immunol Immunother 55 237 245 16047143
79. JL Langowski X Zhang L Wu, et al. 2006 IL-23 promotes tumour incidence and growth Nature 442 461 465 1:CAS:528:DC%2BD28XnsVajtbk%3D 16688182
80. JL Langowski RA Kastelein M Oft 2007 Swords into plowshares: IL-23 repurposes tumor immune surveillance Trends Immunol 28 207 712 1:CAS:528:DC%2BD2sXkslKqsr8%3D 17395538
81. DM Lathers NJ Achille MR Young 2003 Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck Hum Immunol 64 1160 1166 1:CAS:528:DC%2BD3sXptVGqsr4%3D 14630398
82. L Lauerova L Dusek M Simickova, et al. 2002 Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response Neoplasma 49 159 166 1:CAS:528:DC%2BD38XlvFWjsbc%3D 12098001
83. EY Lin AV Nguyen RG Russell, et al. 2001 Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy J Exp Med 193 727 740 1:CAS:528:DC%2BD3MXitFKhsLo%3D 11257139
84. EY Lin JF Li L Gnatovskiy, et al. 2006 Macrophages regulate the angiogenic switch in a mouse model of breast cancer Cancer Res 66 11238 11246 1:CAS:528:DC%2BD28Xht1KnsL%2FI 17114237
85. A Lin WH Yan HH Xu, et al. 2007 HLA-G expression in human ovarian carcinoma counteracts NK cell function Ann Oncol 18 1804 1809 1:STN:280:DC%2BD2snmvFWktA%3D%3D 17846022
86. AA Link T Kino JA Worth, et al. 2000 Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes J Immunol 164 436 442 1:CAS:528:DC%2BD3cXisFWk 10605040
87. Y Liu X Bi S Xu, et al. 2005 Tumor-infiltrating dendritic cell subsets of progressive or regressive tumors induce suppressive or protective immune responses Cancer Res 65 4955 4962 1:CAS:528:DC%2BD2MXks1Ogsro%3D 15930318
88. L Liu B Shan Y Feng 2009 Antitumor effects and immunoregulation mechanisms of IL-23 gene in mouse mammary cancer mediated by retrovirus Cell Immunol 258 181 187 1:CAS:528:DC%2BD1MXotF2ns7o%3D 19500780
89. A Loskog C Ninalga G Paul-Wetterberg, et al. 2007 Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines J Urol 177 353 358 17162090
90. G Luboshits S Shina O Kaplan, et al. 1999 Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma Cancer Res 59 4681 4687 1:CAS:528: DyaK1MXmtVKkt7w%3D 10493525
91. B Ludewig AF Ochsenbein B Odermatt, et al. 2000 Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease J Exp Med 191 795 804 1:CAS:528: DC%2BD3cXhslygt78%3D 10704461
92. TT MacDonald 1998 T cell immunity to oral allergens Curr Opin Immunol 10 620 627 1:CAS:528:DyaK1MXhtlCr 9914215
93. J MacMicking QW Xie C Nathan 1997 Nitric oxide and macrophage function Annu Rev Immunol 15 323 350 1:CAS:528:DyaK2sXisVCmsLo%3D 9143691
94. + T-cells in patients with classical Hodgkin lymphoma Leuk Lymphoma 44 1325 1331 1:CAS:528:DC%2BD3sXlt1Knsbk%3D 12952225
95. S Majewski M Marczak A Szmurlo, et al. 1996 Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo J Invest Dermatol 106 1114 1118 1:CAS:528:DyaK28Xjs1ShurY%3D 8618049
96. KJ Malmberg 2004 Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? Cancer Immunol Immunother 53 879 892 1:CAS:528:DC%2BD2cXntV2hsLY%3D 15338206
97. A Mantovani C Porta L Rubino, et al. 2006 Tumor-associated macrophages (TAMs) as new target in anticancer therapy Drug Discov Today Ther Strategies 3 361 366
98. G McMahon 2000 VEGF receptor signaling in tumor angiogenesis Oncologist 5 suppl 1 3 10 1:CAS:528:DC%2BD3cXjsFartrw%3D 10804084
99. JR McWhirter A Kretz-Rommel A Saven, et al. 2006 Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation Proc Natl Acad Sci USA 103 1041 1046 1:CAS:528: DC%2BD28XhsVKgtbo%3D 16418292
100. M Meyer M Clauss A Lepple-Wienhues, et al. 1999 A novel vascular endothelial growth factor encoded by Orf virus, VEGFE, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases EMBO J 18 363 374 1:CAS:528:DyaK1MXotlenug%3D%3D 9889193
101. CD Mills K Kincaid JM Alt, et al. 2000 M-1/M-2 macrophages and the Th1/Th2 paradigm J Immunol 164 6166 6173 1:CAS:528:DC%2BD3cXktFWlsbw%3D 10843666
102. BJ Moeller Y Cao Z Vujaskovic, et al. 2004 The relationship between hypoxia and angiogenesis Semin Radiat Oncol 14 215 221 15254864
103. PA Monach SC Meredith CT Siegel, et al. 1995 A unique tumor antigen produced by a single amino acid substitution Immunity 2 45 59 1:CAS:528:DyaK2MXjt1ertrk%3D 7600302
104. KW Moore R de Waal Malefyt RL Coffman, et al. 2001 Interleukin-10 and the interleukin-10 receptor Annu Rev Immunol 19 683 765 1:CAS:528: DC%2BD3MXivFKgu70%3D 11244051
105. G Mouillot C Marcou I Zidi, et al. 2007 Hypoxia modulates HLA-G gene expression in tumor cells Hum Immunol 68 277 285 1:CAS:528:DC%2BD2sXjslShsrg%3D 17400064
106. NM Moutsopoulos J Wen SM Wahl 2008 TGF-beta and tumors - an ill-fated alliance Curr Opin Immunol 20 234 240 1:CAS:528:DC%2BD1cXntlSktrY%3D 18486463
107. DH Munn MD Sharma JR Lee, et al. 2002 Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase Science 297 1867 1870 1:CAS:528:DC%2BD38Xnt1Shsro%3D 12228717
108. + T cell tolerance in cancer Nat Med 13 828 835 1:CAS:528:DC%2BD2sXnsFWmt7w%3D 17603493
109. S Namkoong SJ Lee HT Chung, et al. 2006 Prostaglandin E2 stimulates angiogenesis and tumor growth by activating the nitric oxide/cGMP pathway Nitric Oxide 14 A27 A38
110. RP Negus GW Stamp MG Relf, et al. 1995 The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer J Clin Invest 95 2391 2396 1:CAS:528:DyaK2MXltlWru74%3D 7738202
111. RP Negus GW Stamp J Hadley, et al. 1997 Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines Am J Pathol 150 1723 1734 1:STN:280:DyaK2s3ot12lsA%3D%3D 9137096
112. N Nishida H Yano T Nishida, et al. 2006 Angiogenesis in cancer Vasc Health Risk Manag 2 213 219 1:CAS:528:DC%2BD28Xhtlars77L 17326328
113. + regulatory T cells in antitumor immune response J Immunol 175 4433 4440 1:CAS:528:DC%2BD2MXhtVWltbrO 16177085
114. M Numasaki J Fukushi M Ono, et al. 2003 Interleukin-17 promotes angiogenesis and tumor growth Blood 101 2620 2627 1:CAS:528:DC%2BD3sXivVWgu70%3D 12411307
115. DW O'Neill S Adams N Bhardwaj 2004 Manipulating dendritic cell biology for the active immunotherapy of cancer Blood 104 2235 2246 15231572
116. MS O'Reilly T Boehm Y Shing, et al. 1997 Endostatin: an endogenous inhibitor of angiogenesis and tumor growth Cell 88 277 285 9008168
117. A Ogata D Chauhan G Teoh, et al. 1997 IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade J Immunol 159 2212 2221 1:CAS:528:DyaK2sXlslGltb4%3D 9278309
118. A Orimo PB Gupta DC Sgroi, et al. 2005 Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion Cell 121 335 348 1:CAS:528:DC%2BD2MXktlSiu7w%3D 15882617
119. A Östman M Augsten 2009 Cancer-associated fibroblasts and tumor growth-bystanders turning into key players Curr Opin Genet Dev 19 67 73 19211240
120. A Östman CH Heldin 2007 PDGF receptors as targets in tumor treatment Adv Cancer Res 97 247 274 17419949
121. S Ostrand-Rosenberg 2008 Immune surveillance: a balance between protumor and antitumor immunity Curr Opin Genet Dev 18 11 18 1:CAS:528: DC%2BD1cXmsVartLc%3D 18308558
122. Ostrand-Rosenberg S, Sinha P (2008) Macrophages and tumor development. In: Gabrilovich D, Hurwitz A (eds) Tumor-induced immune suppression: mechanisms and therapeutic reversal. Springer, New York
123. C Parham M Chirica J Timans, et al. 2002 A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rb1 and a novel cytokine receptor subunit, IL-23R J Immunol 168 5699 5708 1:CAS:528:DC%2BD38XktFCrtrw%3D 12023369
124. P Pisa E Halapi E Pisa, et al. 1992 Selective expression of interleukin 10, interferon-γ and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies Proc Natl Acad Sci USA 89 7708 7712 1:CAS:528: DyaK38Xls12gtr4%3D 1502188
125. V Pistoia F Morandi X Wang, et al. 2007 Soluble HLA-G: are they clinically relevant? Semin Cancer Biol 17 469 479 1:CAS:528:DC%2BD2sXht12hsrzK 17825579
126. JD Powell MR Horton 2005 Threat matrix: low-molecular-weight hyaluronan (HA) as a danger signal Immunol Res 31 207 218 1:CAS:528:DC%2BD2MXkslymtbo%3D 15888912
127. BA Rabinovich J Li J Shannon, et al. 2003 Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells J Immunol 170 3572 3576 1:CAS:528:DC%2BD3sXitFKltrY%3D 12646619
128. N Raghunand RA Gatenby RJ Gillies 2003 Microenvironmental and cellular consequences of altered blood flow in tumours Br J Radiol 76 S11 S22 15456710
129. JM Reiman M Kmieciak MH Manjili, et al. 2007 Tumor immunoediting and immunosculpting pathways to cancer progression Semin Cancer Biol 17 275 287 1:CAS:528:DC%2BD2sXovFyjs7o%3D 17662614
130. D Ribatti A Vacca R Ria, et al. 2003 Neovascularisation, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma Eur J Cancer 39 666 674 1:CAS:528:DC%2BD3sXhvFGkur0%3D 12628847
131. D Ribatti N Finato E Crivellato, et al. 2005 Neovascularization and mast cells with tryptase activity increase simultaneously with pathologic progression in human endometrial cancer Am J Obstet Gynecol 193 1961 1965 1:CAS:528:DC%2BD2MXht1Olt7nO 16325597
132. PC Rodriguez AC Ochoa 2006 T cell dysfunction in cancer: role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress Semin Cancer Biol 16 66 72 1:CAS:528:DC%2BD28XotVClsg%3D%3D 16298138
133. H Saji M Koike T Yamori, et al. 2001 Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma Cancer 92 1085 1091 1:STN:280:DC%2BD3Mritl2isg%3D%3D 11571719
134. P Sánchez-Rovira E Jimenez J Carracedo, et al. 1998 Serum levels of intercellular adhesion molecule 1 (ICAM-1) in patients with colorectal cancer: inhibitory effect on cytotoxicity Eur J Cancer 34 394 398 9640229
135. E Sapi 2004 The role of CSF-1 in normal physiology of mammary gland and breast cancer: an update Exp Biol Med 229 1 11 1:CAS:528:DC%2BD2cXmsFKisQ%3D%3D
136. B Seliger MJ Maeurer S Ferrone 2000 Antigen-processing machinery breakdown and tumor growth Immunol Today 21 455 464 1:CAS:528: DC%2BD3cXmtVCmsr0%3D 10953098
137. LY Sender K Gibbert Y Suezer, et al. 2010 CD40 ligand-triggered human dendritic cells mount interleukin-23 responses that are further enhanced by danger signals Mol Immunol 47 1255 1261 1:CAS:528:DC%2BC3cXisFSit7k%3D 20071030
138. N Seo S Hayakawa Y Tokura 2002 Mechanisms of immune privilege for tumor cells by regulatory cytokines produced by innate and acquired immune cells Semin Cancer Biol 12 291 300 1:CAS:528:DC%2BD38XlvVSjsLg%3D 12147203
139. P Serafini I Borrello V Bronte 2006 Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression Semin Cancer Biol 16 53 65 1:CAS:528:DC%2BD28XotVCmuw%3D%3D 16168663
140. V Shankaran H Ikeda AT Bruce, et al. 2001 IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity Nature 410 1107 1111 1:CAS:528:DC%2BD3MXjsVCrtr4%3D 11323675
141. JJ Sheu leM Shih 2007 Clinical and biological significance of HLA-G expression in ovarian cancer Semin Cancer Biol 17 436 443 1:CAS:528: DC%2BD2sXht12hsrzO 17681474
142. Y Shi JE Evans KL Rock 2003 Molecular identification of a danger signal that alerts the immune system to dying cells Nature 425 516 521 1:CAS:528:DC%2BD3sXnslSis7g%3D 14520412
143. A Sica A Saccani B Bottazzi, et al. 2000 Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages J Immunol 164 762 767 1:CAS:528: DC%2BD3cXlt1CmsQ%3D%3D 10623821
144. A Sica P Allavena A Mantovani 2008 Cancer related inflammation: the macrophage connection Cancer Lett 267 204 215 1:CAS:528:DC%2BD1cXovF2hsLk%3D 18448242
145. P Sinha VK Clements S Ostrand-Rosenberg 2005 Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis Cancer Res 65 11743 11751 1:CAS:528: DC%2BD2MXhtlWiu7vF 16357187
146. P Sinha VK Clements SK Bunt, et al. 2007 Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response J Immunol 179 977 983 1:CAS:528:DC%2BD2sXnt1Wmtbs%3D 17617589
147. P Sinha VK Clements AM Fulton, et al. 2007 Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells Cancer Res 67 4507 4513 1:CAS:528:DC%2BD2sXltVyrtrY%3D 17483367
148. KS Siveen G Kuttan 2009 Role of macrophages in tumour progression Immunol Lett 123 97 102 1:CAS:528:DC%2BD1MXltlCjsr8%3D 19428556
149. MJ Smyth KY Thia SE Street, et al. 2000 Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma J Exp Med 192 755 760 1:CAS:528:DC%2BD3cXmtlegtrg%3D 10974040
150. MJ Smyth NY Crowe DI Godfrey 2001 NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma Int Immunol 13 459 463 1:CAS:528:DC%2BD3MXivFyju7w%3D 11282985
151. GP Smyth PP Stapleton CB Barden, et al. 2003 Renal cell carcinoma induces prostaglandin E2 and T-helper type 2 cytokine production in peripheral blood mononuclear cells Ann Surg Oncol 10 455 462 12734096
152. X Song Y Krelin T Dvorkin, et al. 2005 CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells J Immunol 175 8200 8208 1:CAS:528:DC%2BD2MXht12jt73M 16339559
153. DE Spaner 2004 Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells J Leukoc Biol 76 338 351 1:CAS:528:DC%2BD2cXmtlKrs7g%3D 15277580
154. SA Stacker MG Achen L Jussila, et al. 2002 Lymphangiogenesis and cancer metastasis Nat Rev Cancer 2 573 583 1:CAS:528:DC%2BD38XlslGqsL4%3D 12154350
155. L Steinman 2007 A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage Nat Med 13 139 145 1:CAS:528:DC%2BD2sXhsVykuro%3D 17290272
156. LA Sullivan RA Brekken 2010 The VEGF family in cancer and antibody-based strategies for their inhibition MAbs 2 165 175
157. KL Talks H Turley KC Gatter, et al. 2000 The expression and distribution of the hypoxia inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages Am J Pathol 157 411 421 1:CAS:528:DC%2BD3cXlvFyru7c%3D 10934146
158. M Terabe J Swann E Ambrosino, et al. 2005 A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance J Exp Med 202 1627 1633 1:CAS:528:DC%2BD2MXhtlCjsrvF 16365146
159. LL Thomsen DW Miles 1998 Role of nitric oxide in tumour progression: lessons from human tumours Cancer Metastasis Rev 17 107 118 1:CAS:528: DyaK1cXisVWqsro%3D 9544426
160. T Ueno M Toi H Saji, et al. 2000 Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer Clin Cancer Res 6 3282 3289 1:CAS:528: DC%2BD3cXmsVOmt7c%3D 10955814
161. S Ugurel V Rebmann S Ferrone, et al. 2001 Soluble HLA-G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy Cancer 92 369 376 1:STN:280:DC%2BD3Mvhs1yqug%3D%3D 11466692 (Pubitemid 32664444)
162. M Urosevic R Dummer 2003 HLA-G and IL-10expression in human cancer-different stories with the same message Semin Cancer Biol 13 337 342 1:CAS:528:DC%2BD3sXptVCntrg%3D 14708713
163. M Urosevic R Dummer 2008 Human leukocyte antigen-G and cancer immunoediting Cancer Res 68 627 630 1:CAS:528:DC%2BD1cXhsF2kt7k%3D 18245459
164. C Uyttenhove L Pilotte I Théate, et al. 2003 Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase Nat Med 9 1269 1274 1:CAS:528:DC%2BD3sXns1Clu7c%3D 14502282
165. R Valenti V Huber M Iero, et al. 2007 Tumor released microvesicles as vehicles of immunosuppression Cancer Res 67 2912 2915 1:CAS:528: DC%2BD2sXksVGlt7o%3D 17409393
166. T Valkovic K Lucin M Krstulja, et al. 1998 Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer Pathol Res Pract 194 335 340 1:CAS:528:DyaK1cXjsleit7k%3D 9651946
167. ME Van den Broek D Kagi F Ossendorp, et al. 1996 Decreased tumor surveillance in perforin-deficient mice J Exp Med 184 1781 1790 8920866
168. BJ Van den Eynde I Théate C Uyttenhove, et al. 2007 Tumoral immune resistance based on tryptophan degradation by indoleamine 2,3-dioxygenase Int Congress Series 1304 274 277
169. T Vial J Descotes 2003 Immunosuppressive drugs and cancer Toxicology 185 229 240 1:CAS:528:DC%2BD3sXhtVCntbY%3D 12581698
170. MS von Bergwelt-Baildon A Popov T Saric, et al. 2006 CD25 and indoleamine 2,3-dioxygenase are upregulated by prostaglandin E2 and expressed by tumor associated dendritic cells in vivo: additional mechanisms of T-cell inhibition Blood 108 228 237
171. RA Walker SJ Dearing B Gallacher 1994 Relationship of transforming growth factor beta 1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma Br J Cancer 69 1160 1165 1:STN:280:DyaK2c3lslCmsg%3D%3D 7515264
172. D Wang RN DuBois 2006 Prostaglandins and cancer Gut 55 115 122 1:CAS:528:DC%2BD28Xnt1yquw%3D%3D 16118353
173. S Wang WS El-Deiry 2003 TRAIL and apoptosis induction by TNF-family death receptors Oncogene 22 8628 8633 1:CAS:528:DC%2BD3sXptFOmur4%3D 14634624
174. S Wang Z Liu L Wang, et al. 2009 NF-kappaB signaling pathway, inflammation and colorectal cancer Cell Mol Immunol 6 327 334 1:CAS:528:DC%2BD1MXhsF2isbfP 19887045
175. + regulatory T cells in human ovarian carcinoma Cancer Res 65 5020 5026 1:CAS:528:DC%2BD2MXltFemtLg%3D 15958543
176. TJ Welsh RH Green D Richardson, et al. 2005 Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer J Clin Oncol 23 8959 8967 16219934
177. S White-Gilbertson L Kasman J McKillop, et al. 2009 Oxidative stress sensitizes bladder cancer cells to TRAIL mediated apoptosis by downregulating anti-apoptotic proteins J Urol 182 1178 1185 1:CAS:528:DC%2BD1MXhtFWrt7zJ 19625063
178. TL Whiteside 2010 Immune responses to malignancies J Allergy Clin Immunol 125 2 suppl 2 S272 S283 20061007
179. L Wicherek M Dutsch P Mak, et al. 2003 Comparative analysis of RCAS1 level in neoplasms and placenta Acta Biochim Pol 50 1187 1194 1:CAS:528:DC%2BD2cXhtFGktLg%3D 14740005
180. JR Wilczynski J Kalinka M Radwan 2008 The role of T-regulatory cells in pregnancy and cancer Front Biosci 13 2275 2289 1:CAS:528:DC%2BD1cXhs1CgtbY%3D 17981709
181. D Wodarz VA Jansen 2003 A dynamical perspective of CTL cross-priming and regulation: implications for cancer immunology Immunol Lett 86 213 227 1:CAS:528:DC%2BD3sXivFerurw%3D 12706524
182. S Wojtowicz-Praga 2003 Reversal of tumor-induced immunosuppression by TGF-beta inhibitors Invest New Drugs 21 21 32 1:CAS:528:DC%2BD3sXisVGjt7g%3D 12795527
183. JD Wu LM Higgins A Steinle, et al. 2004 Prevalent expression of the immunostimulatory MHC class I-related molecule is counteracted by shedding in prostate cancer J Clin Invest 114 560 568 1:CAS:528:DC%2BD2cXmvVelsrk%3D 15314693
184. J Xu JY Zhou WZ Wei, et al. 2010 Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells PLoS One 5 e10226 20419107
185. K Yanagisawa MA Exley X Jiang, et al. 2006 Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide Cancer Res 66 11441 11446 1:CAS:528:DC%2BD28Xht1KnsL3E 17145891
186. H Yoshiji S Kuriyama J Yoshii, et al. 2002 Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma Hepatology 35 834 842 1:CAS:528:DC%2BD38XjtFSks7w%3D 11915029
187. Z Yu MR Theoret CE Touloukian, et al. 2004 Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance J Clin Invest 114 551 559 1:CAS:528:DC%2BD2cXmvVelsrg%3D 15314692
188. P Yu DA Rowley YX Fu H Schreiber 2006 The role of stroma in immune recognition and destruction of well-established solid tumors Curr Opin Immunol 18 226 231 1:CAS:528:DC%2BD28XitVaksbo%3D 16459066
189. H Zhang XF Sun 2002 Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer Am J Gastroenterol 97 1037 1041 1:CAS:528:DC%2BD38XktVKkt7g%3D 12003384
190. JG Zhang L Hepburn G Cruz, et al. 2005 The role of adenosine A2A and A2B receptors in the regulation of TNF-alpha production by human monocytes Biochem Pharmacol 69 883 889 1:CAS:528:DC%2BD2MXhvVCiu74%3D 15748700
191. X Zhang H Huang J Yuan, et al. 2005 CD4-8-dendritic cells prime CD4+ T regulatory 1 cells to suppress antitumor immunity J Immunol 175 2931 2937 1:CAS:528:DC%2BD2MXos1Git78%3D 16116179
192. C Zhou J Borillo J Wu, et al. 2004 Ovarian expression of chemokines and their receptors J Reprod Immunol 63 1 9 1:CAS:528:DC%2BD2cXmt1WltL4%3D 15283999
193. H Zong B Yin J Chen, et al. 2009 Over-expression of c-FLIP confers the resistance to TRAIL-induced apoptosis on gallbladder carcinoma Tohoku J Exp Med 217 203 208 1:CAS:528:DC%2BD1MXkvFCru7g%3D 19282655
194. W Zou V Machelon A Coulomb-L'Hermin, et al. 2001 Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells Nat Med 7 1339 1346 1:CAS:528:DC%2BD3MXovFKmsLc%3D 11726975 (Pubitemid 34007939)